Sun Pharmaceutical Industries. has filed a patent for an anti-IL-23p19 antibody called hum13B8-b, or its antigen binding fragment, for the treatment of plaque psoriasis of the scalp. The patent claims a method of treating psoriasis of the scalp by administering hum13B8-b, which consists of specific amino acid sequences for its light and heavy chain polypeptides. GlobalData’s report on Sun Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Sun Pharmaceutical Industries, Nanoparticle drug conjugates was a key innovation area identified from patents. Sun Pharmaceutical Industries's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of scalp psoriasis using anti-il-23p19 antibody hum13b8-b

Source: United States Patent and Trademark Office (USPTO). Credit: Sun Pharmaceutical Industries Ltd

A recently filed patent (Publication Number: US20230303678A1) describes a method for treating psoriasis of the scalp using an anti-IL-23p19 antibody called hum13B8-b. The method involves administering the antibody to a patient, where hum13B8-b consists of a light chain polypeptide with a specific amino acid sequence and a heavy chain polypeptide with another specific amino acid sequence.

The patent claims that the method is effective for treating moderate to severe psoriasis of the scalp. A therapeutically effective amount of hum13B8-b is administered to the patient, with a first dose given at week 0, a second dose at 4 weeks, and subsequent doses every 4 to 12 weeks thereafter. The first dose, second dose, and subsequent doses can be the same, with a suggested dose of 100 mg.

The subsequent dose can be administered every 12 weeks for at least 16 weeks, every 4 weeks for at least 28 weeks, or every 12 weeks for longer durations such as 40 weeks, 52 weeks, 72 weeks, or more. The antibody is administered to the patient through subcutaneous injection.

The patent also mentions specific criteria for patients who can benefit from this method. These include patients with an affected Scalp Surface Area (SSA) of at least 50%, a Psoriasis Area and Severity Index (PASI) score of at least 16.7, and/or a Physician Global Assessment (PGA) score of 3 ("moderate") or 4 ("severe"). The patient can also be male, White, and at least 44 years of age.

The administration of the antibody is expected to result in the patient achieving an Investigator Global Assessment (IGA) score for the scalp of "clear" or "almost clear" with at least a 2-point reduction from the baseline at Week 12 or Week 16. It can also lead to a Psoriasis Scalp Severity Index (PSSI) 90 at Week 12 or Week 16.

In addition to the method of treatment, the patent also describes a pharmaceutical composition of hum13B8-b for the treatment of plaque psoriasis of the scalp. The composition consists of the same light chain and heavy chain polypeptides and is administered to the patient following a similar dosing schedule as mentioned earlier.

Overall, this patent presents a method and pharmaceutical composition for effectively treating psoriasis of the scalp using an anti-IL-23p19 antibody called hum13B8-b. The method involves specific dosing schedules and criteria for patient selection, with the goal of achieving significant improvement in scalp condition and reducing psoriasis severity.

To know more about GlobalData’s detailed insights on Sun Pharmaceutical Industries, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies